Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk
The Symbicort Patient Identification Resource is a promotional resource, designed to support the NHS to improve the care of patients living with Asthma who may be suitable for Symbicort® in relation to its licence.
Using the GP clinical systems, the Symbicort Patient Identification Resource enables the user to take a systematic, consistent and efficient approach to identify patients who may be considered for Symbicort® in line with the current asthma licence.
SPIR highlights asthma patients who may be over reliant on their SABA (short acting beta-2 agonist) which is associated with poor patient outcomes and an increase in exacerbations.6
Watch the below video to find out more about SPIR, including a case study from Dr Helen Sherrell, GP from Badgerswood Surgery, Hampshire
*Scotland, Wales & Northern Ireland
The Symbicort Patient Identification Resource can be used by GPs, Practice Nurses, Managers and Administrative staff. It is only available for those UK based practices who have access to EMIS, SystmOne and Vision.*
*Scotland, Wales & Northern Ireland
Please consult your local policies and relevant teams for data sharing.
Once you have downloaded and imported the searches onto your GP Clinical System they can be utilised until your practice or AstraZeneca recommends that you delete them.
AstraZeneca may retain certain personal data of the user, including but not limited to the name of registered user, job title, email address and GP Practice name, address and practice identification code.
AstraZeneca will store the name of registered user, job title and email address solely for the purposes of registration and for the purposes of contacting the GP Practice for any Maintenance Releases.
AstraZeneca shall not share any personal data with any other third parties without prior written consent.
AstraZeneca will store all User personal data using adequate security measures and will only store such data for the time period required by local laws and AstraZeneca’s internal policies and procedures.
No, AstraZeneca does not see or receive any patient or practice data.
Star OUTiCO Healthcare Solutions at SPIR-support@Uniphar.co.uk
Please consult your local IT governance policies and relevant teams in relation to IT governance.
The resource will be available to you once you have completed the registration form on the Symbicort Patient Identification Resource website.
You can access the full specification document from within the instruction guide. This details all the criteria, including the coding, used in extraction queries.
The searches have been validated in live GP practices by commissioned HCP's.
AstraZeneca requests individual NHS organisations to request access by completing a registration process via the Symbicort Patient Identification Resource website.
We have received your request and will be in touch with you soon.
Symbicort ® (budesonide/formoterol) Turbohaler® 100/6, 200/6 and 400/12 are indicated for regular treatment of asthma where the combined use of inhaled corticosteroids (ICS) and long-acting β2 adrenoceptor agonist (LABA) is appropriate:1-3
or
Symbicort® Turbohaler® 100/6 is indicated for adult, adolescents and children aged 6 years and older. Symbicort® Turbohaler® 200/6 and 400/12 are indicated for adults and adolescents 12 years and older.
Symbicort® Turbohaler® 100/6 is not intended for the initial management of asthma. It is indicated in patients with asthma aged ≥6 years for regular maintenance treatment with a separate rapid-acting bronchodilator as rescue or as a Maintenance and Reliever Therapy (MART).1
Symbicort® Turbohaler® 200/6 is indicated for patients ≥12 years as reliever therapy for mild asthma and is indicated for maintenance therapy or MART.2
Symbicort® Turbohaler® 400/12 is indicated for maintenance therapy only in asthma patients ≥12 years and is not intended for the initial management of asthma.3
It’s important to note, there is a pressurised metered dose inhaler Symbicort 100/3 pMDI* available for the treatment of asthma, as an alternative for asthma patients who can’t use a dry powder inhaler.4
*The Symbicort 100/3 pMDI is to be used in the treatment of Asthma and is not approved in the UK for the treatment of COPD. An alternative strength of Symbicort pMDI is also available (200/6 micrograms/inhalation), Symbicort 200/6 pMDI is to be used in the treatment of COPD and is not approved in the UK for the treatment of Asthma.4,5
You are strongly advised to consult the respective SmPCs before prescribing for age related dosing, maximum dosage and method of administration for Symbicort Turbohaler 100/6, 200/6, 400/12 and Symbicort 100/3 and 200/6 pMDI. 1-5
GB-73067 I DOP: March 2026
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
